Full Papers
Apoptosis inhibitor of macrophage/CD5L is associated with disease activity in rheumatoid arthritis
X. Wu1, M. Li2, T. Chen3, H. Zhong4, X. Lai5
- Department of Laboratory Medicine, the First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
- Department of Laboratory Medicine, the First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
- Department of Laboratory Medicine, the First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
- Department of Laboratory Medicine, the First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
- Department of Laboratory Medicine, the First Affiliated Hospital of Chongqing Medical University, Chongqing, China. 87936966@qq.com
CER12895
2021 Vol.39, N°1
PI 0058, PF 0065
Full Papers
PMID: 32194022 [PubMed]
Received: 25/10/2019
Accepted : 24/02/2020
In Press: 18/03/2020
Published: 05/02/2021
Abstract
OBJECTIVES:
To investigate the association between apoptosis inhibitor of macrophage (AIM) and disease activity in patients with rheumatoid arthritis (RA).
METHODS:
In this study, concentrations of serum AIM in 110 RA patients, 38 patients with osteoarthritis (OA) and 50 sex- and age-matched control subjects were determined by enzyme-linked immunosorbent assay (ELISA).
RESULTS:
Serum AIM concentrations in RA patients were dramatically higher than those from patients with OA or healthy controls. The levels of synovial fluid AIM displayed a significant increase as compared with OA patients. More importantly, AIM levels were significantly correlated with RA disease activity features such as ESR, CRP and DAS28. The predictive value of AIM on high disease activity was superior to those of CRP and ESR. A noteworthy correlation in our study was observed between the serum AIM levels and laboratory parameters, particularly serum lipids. Furthermore, serum AIM levels could be significantly down-regulated after effective integrative treatment.
CONCLUSIONS:
AIM may serve as a novel sensitive biomarker to assist disease activity assessment and monitor therapeutic effects in active RA patients.
